AOA Dx Follows the 
Exits and Reframes 
Women’s Health
Investors often describe women’s health 
as an emerging opportunity. Anna Jeter 
shared the data to show investors often 
miss real and proven opportunities.  
Jeter, Cofounder and Chief Regulatory 
Officer of Denver-based AOA Dx, has 
worked in women’s health for 15 years 
and participated in two successful exits. 
She and Oriana Papin-Zoghbi, the com­
pany’s Cofounder and CEO, regularly 
heard investors say they were waiting for 
a major outcome to prove the category 
could deliver returns. 
AOA Dx decided to quantify them.
Released at the 2026 J.P. Morgan 
Healthcare Conference, AOA’s “Follow 
the Exits: Why Women’s Health Is a Smart 
Bet in Healthcare” analyzed 272 publicly 
announced exits from 2000 through 2024, 
plus four billion-dollar exits in 2025. The 
report identified more than $100 billion 
in realized value and 27 billion-dollar 

outcomes across diagnostics, biopharma, 
devices, and hybrid platforms.
“What’s been missing isn’t performance, it’s 
measurement,” Jeter says.
Nearly half of the exits occurred in the 
past five years. Diagnostics, biopharma, 
and devices generated close to 80% of 
total exit value. Diagnostics delivered 
median exit values more than twice 
broader benchmarks.
The findings made headlines in major pub­
lications. The data also reached a global 
audience of world leaders through the 
World Economic Forum’s 2026 Women’s 
Health Investment Outlook, which maps 
private capital flows and makes the case 
for women’s health as a large, undercap­
italized healthcare opportunity.
AOA Dx remains focused on its own 
opportunities. Its AKRIVIS GD™ blood 
test is designed to detect ovarian cancer 
earlier in symptomatic women. The com­
pany’s GlycoLocate™ platform integrates 
lipids, metabolites, proteins, clinical data, 
and machine learning to identify cancer-
specific molecular signatures.
A July 2026 peer-reviewed study of 503 
participants strengthened the biolog­
ical foundation for that approach. The 
research found coordinated molecular 
patterns across several biological systems 
and showed why a single biomarker class 
cannot solve early detection.
Colorado supports both the science and 
the company’s growth.
“We chose to be in Colorado because of 
amazing access to talent, lab space, and 
our collaboration with the University of 
Colorado,” Jeter says.
She also credits Colorado BioScience 
Association with helping the team build 
relationships and reach local talent. “It 
provides amazing opportunities to 
network, get to know people in the 
industry and the community, and access 
Colorado talent.”
AOA Dx is changing how investors under­
stand women’s health and revolutionizing 
diagnostics for ovarian cancer, a disease 
too often found after it has advanced. 
“
We chose to be in 
Colorado because 
of amazing access to 
talent, lab space, and 
our collaboration 
with the University 
of Colorado.
A N N A  J E T E R
CO F O U N D E R A N D  C H I E F 
R E G U L AT O RY  O F F I C E R
AOA  DX
The AOA Dx team at work 
in its Denver-area lab. 
The company relocated to 
Colorado in 2024.
2026-27 BIOSCIENCE COLORADO     31

View this content as a flipbook by clicking here.